Armon Sharei, SQZ founder and CEO

SQZ's out­side-the-box man­u­fac­tur­ing method slash­es pro­duc­tion time ear­ly in study

At AS­CO 2021 in June of last year, SQZ Biotech show­cased a glimpse of its un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech. And on Wednes­day, the Wa­ter­town, MA, com­pa­ny an­nounced that its first-gen­er­a­tion sys­tem showed com­pa­ra­ble or bet­ter per­for­mance than a con­ven­tion­al clean-room-based man­u­fac­tur­ing process.

The study was non-clin­i­cal. Clin­i­cal tri­als are ex­pect­ed by the first half of 2023.

SQZ’s de­vice opens up a tem­po­rary win­dow by cell-squeez­ing to de­liv­er car­goes in­to cells. Its av­er­age pro­cess­ing time was less than six hours per batch, which is more than half the time than con­ven­tion­al meth­ods. The com­pa­ny is plan­ning to use the tech­nol­o­gy in its first red blood cell de­rived pro­gram for celi­ac dis­ease. That IND is set to be sub­mit­ted in the first half of 2023, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.